NEW YORK–(BUSINESS WIRE)– IRX Therapeutics, Inc. (IRX) today announced that Mark Leuchtenberger,
the Company’s President and Chief Executive Officer, will present a
corporate overview at the BioCentury 24th Annual Future
Leaders in the Biotech Industry Conference on Friday, April 7, 2017, at
3:00 p.m. Eastern time. The conference will be held at the Millennium
Broadway Hotel & Conference Center in New York City.
About IRX Therapeutics
IRX Therapeutics is a clinical-stage company developing novel
immunotherapies focused on reducing the immune suppression that is seen
in the cancer tumor micro-environment, restoring immune function, and
activating a coordinated immune response against the tumor. The lead
candidate, IRX-2, is a proprietary therapeutic containing numerous
active cytokine components. Data collected to date indicates that IRX-2
acts to restore and activate multiple immune cell types, including T
cells, dendritic cells, and natural killer cells, to recognize and
destroy tumors. For more information about the Company and its clinical
programs, please visit www.IRXTherapeutics.com.
Image may be NSFW.
Clik here to view.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170403005935/en/
Source: IRX Therapeutics, Inc.
Cet article IRX Therapeutics to Present at the BioCentury 24th
Annual Future Leaders in the Biotech Industry Conference est apparu en premier sur EEI-BIOTECHFINANCES.
